Update for the half year ended 30 September 2018
Decision will assure future stability of SI
The 2018 ranking is an improvement on last year’s rank of 63
Significant investment at Kulmbach site expands capacity of specialist therapeutic oligonucleotide development solutions business
Investment follows other acquisitions in oligonucleotide reagent and synthesised oligonucleotides markets
National Measurement Laboratory at LGC welcomes recent special report
LGC operates out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India.